Business Context and Reporting Period
This Form 8-K filing by Glucotrack, Inc. (GCTK) covers events occurring on January 27, 2025, through January 29, 2025. The report details a significant change in executive leadership, specifically the resignation of the Chief Financial Officer (CFO) and the immediate appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and the terms of the new CFO's employment agreement.
Material Changes
- Resignation: James Cardwell resigned as Chief Financial Officer effective January 27, 2025. He will remain with the company in a consulting capacity to assist with the transition.
- Appointment: Peter C. Wulff was appointed Chief Financial Officer on January 28, 2025. Mr. Wulff brings over 40 years of experience in the life sciences industry, having previously served as CFO for Biological Dynamics, Inc., JenaValve Technology, Inc., and other medical technology firms.
Guidance, Outlook, and Compensation Terms
The filing outlines the compensation structure for the new CFO, which includes performance-based incentives tied to financing milestones:
- Base Salary: $300,000 for fiscal year 2025, increasing to $450,000 for fiscal year 2026 and thereafter.
- 2025 Performance Bonuses (Financing Milestones):
- $75,000 upon closing transactions totaling $6 million.
- Additional $125,000 upon closing transactions with a cumulative value of $12 million.
- Additional $62,500 upon closing transactions with a cumulative value of $18 million.
- 2026+ Performance Bonus: Up to 15% of the Base Salary contingent on meeting relevant targets.
- Equity Grant: Initial options to purchase shares equal to 1.25% of the Company's outstanding common stock as of the agreement's effective date. A potential additional grant is contingent on employment through December 31, 2025, and the achievement of financial transaction goals.
Investor Verification Checklist
- Verify the exact number of outstanding common shares to calculate the specific share count of the 1.25% equity grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for termination provisions and clawback clauses.
- Monitor upcoming filings for updates on the financing milestones required to trigger the 2025 performance bonuses.
- Confirm the transition timeline for the CFO role to ensure continuity in financial reporting.